Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Proteomic Analysis of Waldenstrom Macroglobulinemia
Hatjiharissi, Evdoxia , Ngo, Hai T., Leontovich, Alexey A. , Leleu, Xavier , Timm, Michael, Melhem, Mona F., George, Diane, Lu, Ganwei, Alsayed, Yazan, Zeismer, Steven C., Cabanela, Miguel E., Nehme, Alex, Jia, Xiaoying , Moreau, Anne Sophie, Fonseca, Rafaël , Ghobrial, Joanna M. , Moreau, Anne Sophie, Treon, Steven P. , Gertz, Morie A. , Anderson, Kenneth C. , Witzig, Thomas E. , Ghobrial, Irene M. , Fonseca, Rafael

Mayo Clinic

Cancer Research | April 17, 2007 | Volume: 67 | Issue: 8 | Pages: 3777-3784

10.1158/0008-5472.can-06-3089 | PMID 17440091 Get It

Abstract To better understand the molecular changes that occur in Waldenstrom macroglobulinemia (WM), we employed antibody-based protein microarrays to compare patterns of protein expression between untreated WM and normal bone marrow controls. Protein expression was defined as a >2-fold or 1.3-fold change in at least 67% of the tumor samples. Proteins up-regulated by >2-fold included Ras family proteins, such as Rab-4 and p62DOK, and Rho family proteins, such as CDC42GAP and ROKα. Other proteins up-regulated by >1.3-fold included cyclin-dependent kinases, apoptosis regulators, and histone deacetylases (HDAC). We then compared the samples of patients with symptomatic and asymptomatic WM and showed similar protein expression signatures, indicating that the dysregulation of signaling pathways occurs early in the disease course. Three proteins were different by >2-fold in symptomatic versus asymptomatic, including the heat shock protein HSP90. Elevated protein expression was confirmed by immunohistochemistry and immunoblotting. Functional significance was validated by the induction of apoptosis and inhibition of proliferation using specific HDAC and HSP90 inhibitors. This study, therefore, identifies, for the first time, multiple novel proteins that are dysregulated in WM, which both enhance our understanding of disease pathogenesis and represent targets of novel therapeutics. [Cancer Res 2007;67(8):3777–8]
Two Common Chromosome 8q24 Variants Are Associated with Increased Risk for Prostate Cancer
McDonnell, Shannon K. , Slusser, Joshua P. , Hebbring, Scott J. , Cunningham, Julie M. , Jacobsen, Steven J. , Cerhan, James R. , Blute, Michael L., Schaid, Daniel J. , Thibodeau, Stephen N. , Wang, Liang , Cerhan, James R , McDonnell, Shannon K

Mayo Clinic

Cancer Research | April 5, 2007 | Volume: 67 | Issue: 7 | Pages: 2944-2950

10.1158/0008-5472.can-06-3186 | PMID 17409399 Get It

Abstract Two variants (rs1447295/DG8S737) of chromosome 8q24 were recently reported to be associated with increased risk of prostate cancer (PC). To confirm this finding, we genotyped and compared the frequencies of these polymorphisms among 1,121 Caucasian men with PC (435 men with familial PC, 491 men with sporadic PC, and 195 men with aggressive PC) to 545 population-based controls. For the single nucleotide polymorphism marker rs1447295, frequencies of the minor allele (A) were 10.3% in controls, 11.9% in sporadic cases, 16.7% in familial cases, and 17.2% in aggressive cases. Compared with controls, the A allele was significantly more common in both familial PC [odds ratios (OR), 1.93; 95% confidence intervals (95% CI), 1.37–2.72; P = 0.0004] and aggressive PC (OR, 1.87; 95% CI, 1.28–2.74; P = 0.0005) but not for sporadic PC (OR, 1.16; 95% CI, 0.85–1.58; P = 0.25). Although the A allele was more frequent in aggressive PC cases when compared with controls, the allele frequencies were similar among cases with high- and low-grade PC (Gleason grades <7 and ≥7, respectively). For the microsatellite marker DG8S737, the −8 allele was significantly more frequent in familial PC (OR, 1.68; 95% CI, 1.09–2.60; P = 0.031), whereas the −10 allele was more frequent in aggressive PC (OR, 2.85; 95% CI, 1.52–5.36; P = 0.0004). Haplotype analysis showed significant differences in haplotype frequencies between the familial PC (P = 0.006) and aggressive PC (P = 0.005) cases versus controls. The −8/A haplotype showed the strongest association with familial PC (P = 0.008), whereas the −10/A haplotype was most strongly associated with aggressive PC (P = 0.00005). These results further confirm the importance of these two polymorphic variants (rs1447295 and DG8S737) as risk factors for PC. However, the mechanism explaining this increased risk has not yet been established. [Cancer Res 2007;67(7):2944–50]
Diabetes and Sexual Dysfunction: Results From the Olmsted County Study of Urinary Symptoms and Health Status Among Men
Burke, J. P., Jacobson, Debra J., McGree, Michaela E. , Nehra, Ajay, Roberts, Rosebud O., Lieber, Michael M., Jacobsen, Steven J. , Girman, Cynthia J.

Mayo Clinic

Journal of Urology | March 24, 2007 | Volume: 177 | Issue: 4 | Pages: 1438-1442

10.1016/j.juro.2006.11.059 | PMID 17382749 Get It

REVIEW ■ : Molecular Basis of Congenital Myasthenic Syndromes: Mutations in the Acetylcholine Receptor
Engel, Andrew G. , Ohno, Kinji , Milone, Margherita , Sine, Steven M. , Wang, Hailong

Mayo Clinic

The Neuroscientist | March 17, 2007 | Volume: 4 | Issue: 3 | Pages: 185-194

10.1177/107385849800400314 Get It

The congenital myasthenic syndromes include end-plate (EP) acetylcholinesterase deficiency, presynaptic abnormalities affecting the evoked release or size of transmitter quanta, and acetylcholine (ACh) receptor (AChR) channelopathies stemming from a kinetic abnormality and/or deficiency of AChR. A kinetic abnor mality predicts, and AChR deficiency may predict, one or more mutations in an AChR subunit gene. These clues have led to the identification of 53 mutations in different subunits of AChR in 55 kinships of the congenital myasthenic syndromes. The mutations either increase or decrease the response to ACh, produce AChR deficiency, or both. In the slow-channel syndromes, prolonged opening episodes of AChR cause cationic overloading of the EP and an EP myopathy; the mutations occur in different subunits and different domains of the subunits and have dominant positive effects. The M1 and M2 mutations slow channel closure, increase apparent affinity for ACh, and variably enhance desensitization, and the extracellular αG153S enhances affinity for ACh, promoting reopening of the diliganded receptor. In the low-affinity fast-channel syndrome, εP121L reduces affinity for ACh and reopening of the diliganded receptor, resulting in a de creased response to ACh and shorter burst durations. Severe EP AChR deficiency results from heterozy gous or homozygous mutations that terminate translation prematurely; these are concentrated in the ε subunit, probably because substitution of the fetal γ for the adult ε subunit can rescue the phenotype from fatal null mutations in ε. Variable AChR deficiency and variable functional abnormalities stem from hetero allelic nonsense and missense mutations in AChR subunit genes. NEUROSCIENTIST 4:185-194, 1998
Gemcitabine Plus Cisplatin in Advanced Pancreatic Cancer
McWilliams, Robert R. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | March 16, 2007 | Volume: 25 | Issue: 9 | Pages: 1142-1142

10.1200/jco.2006.09.0035 | PMID 17369580 Get It

Prevalence and Prognostic Significance of Heart Failure Stages
Ammar, Khawaja Afzal , Jacobsen, Steven J. , Kors, Jan A. , Redfield, Margaret M. , Burnett, John C. , Rodeheffer, Richard J. , Mahoney, Douglas W.

Mayo Clinic

Circulation | March 13, 2007 | Volume: 115 | Issue: 12 | Pages: 1563-1570

10.1161/circulationaha.106.666818 | PMID 17353436 Get It

Background— Heart failure (HF) is a progressive disorder associated with frequent morbidity and mortality. An American Heart Association/American College of Cardiology staging classification of HF has been developed to emphasize early detection and prevention. The prevalence of HF stages and their association with mortality are unknown. We sought to estimate HF stage prevalence in the community and to measure the association of HF stages with mortality. Methods and Results— A population-based, cross-sectional, random sample of 2029 Olmsted County, Minnesota, residents aged ≥45 years was identified. Participants were classified by medical record review, symptom questionnaire, physical examination, and echocardiogram as follows: stage 0, healthy; stage A, HF risk factors; stage B, asymptomatic cardiac structural or functional abnormalities; stage C, HF symptoms; and stage D, severe HF. In the cohort, 32% were stage 0, 22% stage A, 34% stage B, 12% stage C, and 0.2% stage D. Mean B-type natriuretic peptide concentrations (in pg/mL) increased by stages: stage 0=26, stage A=32, stage B=53, stage C=137, and stage D=353. Survival at 5 years was 99% in stage 0, 97% in stage A, 96% in stage B, 75% in stage C, and 20% in stage D. Conclusions— The present study provides prevalence estimates and prognostic validation for HF staging in a community cohort. Of note, 56% of adults ≥45 years of age were classified as being in stage A (risk factors) or B (asymptomatic ventricular dysfunction). HF staging underscores the magnitude of the population at risk for progression to overt HF.
Telecare for Patients With Type 1 Diabetes and Inadequate Glycemic Control
Smith, Steven A., Kudva, Yogish C. , Montori, Víctor M. , Guyatt, Gordon

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 28 | Issue: 1 | Pages: 229-230

10.2337/diacare.28.1.229 Get It

Randomized Controlled Clinical Trial of Glargine Versus Ultralente Insulin in the Treatment of Type 1 Diabetes
Kudva, Yogish C. , Basu, Ananda , Jenkins, Gregory D. , Pons, Guillermo, Quandt, Lori L., Gebel, Julie A., Vogelsang, Debra A., Smith, Steven A., Rizza, Robert A., Isley, William L.

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 28 | Issue: 1 | Pages: 10-14

10.2337/diacare.28.1.10 | PMID 15616226 Get It

OBJECTIVE—Multiple daily insulin injection programs are commonly accompanied by considerable glycemic variation and hypoglycemia. We conducted a randomized crossover design clinical trial to compare glargine with ultralente insulin as a basal insulin in type 1 diabetes. RESEARCH DESIGN AND METHODS—To determine whether the use of glargine insulin as a basal insulin would result in a comparable HbA1c and less glycemic variation and hypoglycemia than ultralente insulin, 22 individuals (aged 44 ± 14 years [±SD], 55% men) with type 1 diabetes who were experienced with multiple daily insulin injections and had an HbA1c of <7.8% were randomized in a crossover design to receive either glargine or ultralente as the basal insulin for 4 months. Aspart insulin was used as the prandial insulin. Physicians providing insulin dose adjustment advice were masked to the type of basal insulin. RESULTS—Treatment with glargine resulted in lower mean HbA1c (6.82 ± 0.13 vs. 7.02 ± 0.13, difference: 0.2 ± 0.08, P = 0.026), less nocturnal variability (plasma glucose 49.06 ± 4.74 vs. 62.36 ± 5.21 mg/dl, P = 0.04), and less hypoglycemia (24.5 ± 2.99 vs. 31.3 ± 4.04 events, P = 0.05), primarily due to less daytime hypoglycemia (P = 0.002). On the other hand, serious hypoglycemia and average glucose concentration measured with continuous subcutaneous glucose monitoring did not differ. CONCLUSIONS—We conclude that while use of either ultralente or glargine as a basal insulin can result in excellent glycemic control, treatment with glargine is associated with slightly but significantly lower HbA1c and less nocturnal glycemic variability and hypoglycemia.
Telecare for Patients With Type 1 Diabetes and Inadequate Glycemic Control
Montori, Víctor M. , Helgemoe, Pamela K., Dean, Diana S., Leung, Teresa W., Smith, Steven A., Kudva, Yogish C. , Helgemoe, Pamela, Guyatt, Gordon , Montori, Victor M

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 27 | Issue: 5 | Pages: 1088-1094

10.2337/diacare.27.5.1088 | PMID 15111526 Get It

OBJECTIVE—To determine the efficacy of telecare (modem transmission of glucometer data and clinician feedback) to support intensive insulin therapy in patients with type 1 diabetes and inadequate glycemic control. RESEARCH DESIGN AND METHODS—Thirty-one patients with type 1 diabetes on intensive insulin therapy and with HbA1c >7.8% were randomized to telecare (glucometer transmission with feedback) or control (glucometer transmission without feedback) for 6 months. The primary end point was 6-month HbA1c. To place our findings in context, we pooled HbA1c change from baseline reported in randomized trials of telecare identified in a systematic review of the literature. RESULTS—Compared with the control group, telecare patients had a significantly lower 6-month HbA1c (8.2 vs. 7.8%, P = 0.03, after accounting for HbA1c at baseline) and a nonsignificant fourfold greater chance of achieving 6-month HbA1c ≤7% (29 vs. 7%; risk difference 21.9%, 95% CI −4.7 to 50.5). Nurses spent 50 more min/patient giving feedback on the phone with telecare patients than with control patients. Meta-analysis of seven randomized trials of adult patients with type 1 diabetes found a 0.4% difference (95% CI 0–0.8) in HbA1c mean change from baseline between the telecare and control groups. CONCLUSIONS—Telecare is associated with small effects on glycemic control in patients with type 1 diabetes on intensive insulin therapy but with inadequate glycemic control.
Decisional Attributes of Patients With Diabetes
Montori, Víctor M. , Bryant, Sandra C. , Jorgensen, Neal W. , Walsh, Erin E., Smith, Steven A., O'Connor, Annette M. Cormier , Montori, Victor M

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 26 | Issue: 10 | Pages: 2804-2809

10.2337/diacare.26.10.2804 | PMID 14514583 Get It

OBJECTIVE—The aim of this study was to determine personal characteristics and preferences that affect decision making (decisional attributes) in patients with diabetes. In particular, we were interested in relating these attributes to the choice of using aspirin to reduce cardiovascular risk. RESEARCH DESIGN AND METHODS—We conducted a cross-sectional survey (70% response rate) of 206 diabetic patients (median age, 63 years; 42% women; 91% completed high school; median HbA1c, 8%) attending a tertiary care diabetes clinic. Patients answered a 42-question survey exploring decisional attributes. Medical records provided the source of clinical information. We evaluated sociodemographic, clinical, and decisional predictors of aspirin use. We also conducted a multivariable analysis with aspirin use as a dependent variable. RESULTS—Sixty-seven percent of patients surveyed used aspirin. Patients using aspirin were at higher risk of cardiovascular disease (odds ratio 1.4, 95% CI 1.0–2.1), knew more about the benefits of aspirin (1.9, 1.4–2.6) and less about the risks of aspirin (1.4, 1.2–1.8), and were more certain about using aspirin (0.5, 0.3–0.8) than patients not using aspirin. Patients using aspirin placed a higher value on preventing cardiovascular events than on avoiding the side effects of aspirin. Patients perceived that their diabetes provider and the American Diabetes Association had greater influence on their decision to use aspirin than family members or other patients with diabetes. CONCLUSIONS—The decisional attributes of patients with diabetes are associated with aspirin use. Decisional attributes may be the target of research and interventions to reduce underutilization to levels consistent with patient preferences.